Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 1 Incidence of new diabetes according to study and drug treatment. *The risk ratio presented is either the relative risk or hazard ratio and 95% confidence interval (CI), as published.  Mean years of follow-up.  With or without background beta-blockers (BBs) and diuretics.  The relative risk and 95% CI were estimated from data provided in publication, using the Mantel-Haenszel method. ||Reported as the percentage of patients with fasting blood sugar at year 4 (C, n = 2,606; A, n = 1,567; L, n = 1,464). ¶Total follow-up for each patient. Solid bars = BBs/diuretics; open bars = angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB)/calcium antagonist (CA). DB = double blind; PROBE = prospective randomized open blinded end point. CAPPP = Captopril Prevention Project; INSIGHT = Intervention as a Goal in Hypertension Treatment; LIFE = Losartan Intervention For Endpoint reduction; ALLHAT = Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial; ANBP2 = Second Australian National Blood Pressure Study; ALPINE = Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation; CHARM = Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity; INVEST = International Verapamil-Trandolapril Study.
|
